Reading IRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IRMD free→Reading IRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IRMD free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady. Earnings quality is mixed, and risk is moderate, while the sector backdrop is a headwind. Peer multiples imply a price about 101% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified, as it is rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. Key factors to watch include guidance changes and sector trends from major players like ABT, SYK, and MDT. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $90.79. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $91 IRMD trades at 47× p/e — 2.0× the 23× p/e peer median. The market is re-rating it beyond its own range; our $43 fair value is low-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 110% near-term growth, well above our forecast of about 17%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, weak execution quality, a turbulent sector regime (Heating).
For similar setups historically (n=889): about 49% saw a 20%+ drawdown, and roughly 85% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.23x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.47 → $0.44 (-5.4% / 30d). 0 raised, 1 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$137.
How much price usually moves either way.
On a bad day, this stock has moved -$300.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,062.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth picks up, it could signal a positive shift for iRadimed and its peers. This would help iRadimed's performance in a maturing market.
Confirms:Health care revenue growth is speeding up again. It is close to 10% or more.
Disproves:Revenue growth is under 10%. This shows it is slowing down.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for IRMD yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 1, 2026 , IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subj…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
IRMD iRadimed Corp. | Typical Show detailsSector percentile: 65 of 100 | expensive | moderate |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Met or beat guidance 100% of the last 2 guided quarters · 14.4% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on the commercialization of the next-generation 3870 MRI IV pump to drive growth.
Newly stated in 2025-Q4. The company has not yet provided specific financial results or milestones related to the commercialization of the 3870 MRI IV pump. Current financials show revenue of $21.98M in 2026-Q1, but no specific impact from the new product is detailed. Persistent statement, limited substantive delivery this quarter.
“the commercialization of our next-generation 3870 MRI IV pump, which we believe will drive additional growth in 2026 and beyond.”
Continue to grow revenue with a focus on achieving full-year guidance.
Stated in 2 of last 2 quarters. Revenue was $21.98M in 2026-Q1, down from $22.69M in 2025-Q4. The company maintains its full-year revenue guidance of $91M to $96M, but the trajectory shows limited progress this quarter.
Focus on achieving the EPS guidance range of $1.90 to $2.05 for 2026.
Stated in 2 of last 2 quarters. EPS was $0.45 in 2026-Q1, aligning with the quarterly guidance range. The company reaffirms its full-year EPS guidance of $1.90 to $2.05, indicating a trajectory that is delivering within expectations so far.
“GAAP diluted earnings per share of $1.90 to $2.05.”
Results of Operations and Financial Condition. On February 10, 2026, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherw…
Other Events. On December 5, 2025, the Board of Directors of IRADIMED CORPORATION declared a special cash dividend on the Company's outstanding common stock of $0.50 per share. The special dividend is payable on December 30, 2025, to shareholders of record at the close of business on December 17, 2025. The information in this Item 8.01, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the lia…
Results of Operations and Financial Condition. On November 3, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherw…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Anthony Vuoto Retirement On August 27, 2025, Anthony Vuoto provided notice of his retirement from his position as a director of the board of directors (the “ Board ”) of Iradimed Corporation, a Delaware corporation (the “ Company ”), and as member of the Audit Committee of the Board (the “ Audit Committee ”) and the chairman of the Compensation C…
“we reaffirm our guidance for the full-year 2026 with revenue of $91.0 million to $96.0 million.”
“we expect to report revenue in the range of $91.0 million to $96.0 million.”
“GAAP diluted earnings per share in the range of $1.90 to $2.05.”